Care after premenopausal risk‐reducing salpingo‐oophorectomy in high‐risk women: Scoping review and international consensus recommendations
Denise Nebgen, Susan M. Domchek, Joanne Kotsopoulos, Joanne A. de Hullu, Emma J. Crosbie, Vincent Singh Paramanandam, Monique M.A. Brood-van Zanten, Barbara M. Norquist, Theresa A. Guise, Serge Rozenberg, Allison W. Kurian, Holly J. Pederson, Nesé Yuksel, Rachel Michaelson‐Cohen, Sharon L. Bober, Agnaldo Lopes da Silva Filho, Nora Johansen, F Guidozzi, D. Gareth Evans, Usha Menon, Sheryl A. Kingsberg, C. Bethan Powell, Giovanni Grandi, Cláudia Marchetti, Michelle Jacobson, Donal J. Brennan, Martha Hickey
Abstract
Women at high inherited risk of ovarian cancer are offered risk-reducing salpingo-oophorectomy (RRSO) from age 35 to 45 years. Although potentially life-saving, RRSO may induce symptoms that negatively affect quality of life and impair long-term health. Clinical care following RRSO is often suboptimal. This scoping review describes how RRSO affects short- and long-term health and provides evidence-based international consensus recommendations for care from preoperative counselling to long-term disease prevention. This includes the efficacy and safety of hormonal and non-hormonal treatments for vasomotor symptoms, sleep disturbance and sexual dysfunction and effective approaches to prevent bone and cardiovascular disease.